Epizyme Inc (NASDAQ:EPZM) shares traded up 19.2% on Thursday . The stock traded as high as $15.00 and last traded at $14.90. 784,200 shares traded hands during mid-day trading, an increase of 45% from the average session volume of 541,343 shares. The stock had previously closed at $12.50.

Several research analysts have weighed in on the company. Morgan Stanley assumed coverage on Epizyme in a report on Wednesday. They issued an “overweight” rating and a $20.00 price target for the company. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Oppenheimer set a $26.00 price objective on shares of Epizyme and gave the company a “buy” rating in a research note on Tuesday, December 12th. Finally, Cann reissued a “buy” rating and set a $26.00 price objective on shares of Epizyme in a research note on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $22.40.

The firm has a market cap of $1,030.00, a P/E ratio of -6.54 and a beta of 2.00.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. equities research analysts expect that Epizyme Inc will post -2.23 EPS for the current fiscal year.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total transaction of $246,600.00. Following the completion of the sale, the insider now directly owns 23,123 shares of the company’s stock, valued at approximately $380,142.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 25.20% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its position in Epizyme by 3.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 1,068 shares during the period. Rhumbline Advisers boosted its position in Epizyme by 2.6% during the 2nd quarter. Rhumbline Advisers now owns 50,140 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 1,257 shares during the period. Principal Financial Group Inc. boosted its position in Epizyme by 1.5% during the 2nd quarter. Principal Financial Group Inc. now owns 95,572 shares of the biopharmaceutical company’s stock worth $1,443,000 after purchasing an additional 1,399 shares during the period. California Public Employees Retirement System boosted its position in Epizyme by 2.2% during the 2nd quarter. California Public Employees Retirement System now owns 135,500 shares of the biopharmaceutical company’s stock worth $2,046,000 after purchasing an additional 2,900 shares during the period. Finally, Teachers Advisors LLC boosted its position in Epizyme by 5.8% during the 2nd quarter. Teachers Advisors LLC now owns 73,952 shares of the biopharmaceutical company’s stock worth $1,117,000 after purchasing an additional 4,030 shares during the period. 85.28% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/epizyme-epzm-trading-19-2-higher/1805335.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.